Canaccord Genuity Maintains Hold on Definitive Healthcare, Raises Price Target to $10
Portfolio Pulse from Benzinga Newsdesk
Canaccord Genuity analyst David Hayes maintains a Hold rating on Definitive Healthcare (NASDAQ:DH) and raises the price target from $9 to $10.
February 29, 2024 | 3:14 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Canaccord Genuity maintains a Hold rating on Definitive Healthcare and raises the price target from $9 to $10.
The increase in price target by Canaccord Genuity suggests a positive outlook on Definitive Healthcare's stock value in the short term, potentially leading to increased investor interest and a positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 90